月度归档： 2026 年 5 月

　　为加快推进特色林果生产向机械化、智能化、绿色化转型，有效破解桃园等林果产业装备适配性不足、技术应用不规范、农机农艺融合不紧密等堵点难点，4月27日至28日，江苏省灌南县农业农村局组织举办桃园生产智能装备与技术培训暨现场演示活动。来自省市…

　　为深入贯彻落实国家和自治区关于耕地占补平衡制度改革的决策部署，履行好补充耕地质量验收工作职责，规范验收流程，提升全区专业技术队伍技能水平，自治区农牧厅、自治区农牧业技术推广中心以全区基层农技人员知识更新培训为契机，4月24 日、29日，…

The companies Kailera Therapeutics, Nektar Therapeutics, and Hemab Therapeutics bagged the biggest biotech funding rounds overall in April 2026 across private and public funding types. In this article, we break down last month’s private and public fundraising activity, looking at the largest rounds in more detail.

Trispecific antibodies are emerging as one of the most exciting drug classes in biopharma, building on the clinical success of bispecific antibodies to deliver even greater efficacy and precision. By simultaneously engaging three distinct targets, these new molecules are designed to address some of the key limitations seen with earlier cancer immunotherapies, such as antigen escape, tumor heterogeneity, and suboptimal immune activation. Meanwhile, they could also be extremely promising in autoimmune and inflammatory indications due to their ability to block multiple pathways. 

After years of momentum behind antibody–drug conjugates (ADCs) and targeted protein degraders, the biotech industry is beginning to wonder: what happens when you try to combine them? The answer may lie in degrader-antibody conjugates, an emerging modality that is drawing increasing interest from next-generation biotech companies. Although still in its infancy, the field is evolving quickly, and competition is already taking shape as big pharma tentatively dips its toes into the space.  

PARP inhibitors are built on the idea of exploiting weaknesses in how tumor cells repair DNA. Among the different repair systems, PARP (poly ADP-ribose polymerase) enzymes are involved in fixing single-strand DNA breaks. When PARP detects damage, it binds to DNA and recruits other repair proteins to resolve it. 

Atopic dermatitis is a chronic, relapsing inflammatory skin disorder characterized by eczematous lesions and intense itchiness, which can substantially impair an individual’s quality of life. Over the past decade, advances in immunological understanding – particularly the central role of type 2 inflammation, an immune response that frequently overreacts to allergens – have driven a therapeutic shift from broad immunosuppression toward more targeted, mechanism-based interventions. While established treatments have significantly improved people’s ability to control their symptoms, many patients remain inadequately treated due to the disease’s persistent nature. This highlights the need for additional options, and, consequently, a diverse pipeline of new atopic dermatitis treatments is currently under investigation, spanning both validated pathways and novel immunological targets. 

The past year saw a string of pipeline cuts and downsizing plans strike the biotech job market. Have layoffs spooked young professionals looking for a way into the industry, and does the employment landscape seem to be looking up this year?

Discovered just over a decade ago, CRISPR has revolutionized the biomedical industry thanks to the fact it allows scientists to target diseases – particularly genetic ones – that were previously untreatable by making direct edits to genes. However, despite being versatile, CRISPR has limitations – while it is ideal for breaking problematic genes and making small edits, it is not very useful when it comes to inserting whole genes or large chunks of DNA. Now, though, the recent discovery of a molecular oddity known as bridge RNA, found in bacteria, could lead to a new gene editing technique that can overcome these limitations.